Fulminant encephalopathy with basal ganglia hyperintensities in HIV-infected drug users

Objective: To define a clinical syndrome associated with active drug abuse in HIV-infected individuals. Methods: We performed a retrospective review to identify individuals treated at the Johns Hopkins Hospital from 1993 to 2008 who were HIV-infected and were actively abusing drugs and had bilateral basal ganglia lesions on MRI. They were identified using a key word search in the radiology database, autopsy database, and the Moore HIV clinic database. Clinical, laboratory, and radiographic findings were correlated to define the syndrome. Results: Ten individuals were identified who presented with a change in mental status or seizures, used cocaine or cocaine with heroin, had uncontrolled HIV infection (>190,000 copies/mL of plasma), elevated CSF protein (63–313 mg/dL), and diffuse hyperintense bilateral basal ganglia lesions on imaging. The majority of patients (8/10) had renal failure and despite supportive therapy most (7/9) ultimately died (median survival 21 days). Postmortem examination in one individual showed the presence of overwhelming microglial activation in the basal ganglia. The 2 surviving individuals were started on combined antiretroviral therapy (CART) during hospitalization. Conclusion: We describe a unique clinical syndrome of a fulminant encephalopathy associated with primarily basal ganglia involvement in HIV-infected drug abusers. This syndrome is a rare but serious condition that is associated with a high mortality rate. Early CART institution may be useful and neuroprotective in this disorder, although this requires further investigation.

[1]  A. Winston,et al.  EFFECTS OF ACTIVE HCV REPLICATION ON NEUROLOGIC STATUS IN HIV RNA VIRALLY SUPPRESSED PATIENTS , 2010, Neurology.

[2]  A. Nath,et al.  Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV‐1 tat transgenic mice , 2008, Glia.

[3]  Mardge H. Cohen,et al.  Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women , 2008, AIDS.

[4]  K. Joynt,et al.  Comorbid HIV Encephalopathy and Cocaine Use as a Risk Factor for New-onset Seizure Disorders , 2008, CNS Spectrums.

[5]  T. Yong,et al.  Bilateral basal ganglia lesions in patients with end‐stage diabetic nephropathy (Brief Communication) , 2008, Nephrology.

[6]  J. Fleishman,et al.  The impact of illicit drug use and substance abuse treatment on adherence to HAART , 2007, AIDS care.

[7]  J. Reynolds,et al.  Proteomic analysis of the effects of cocaine on the enhancement of HIV-1 replication in normal human astrocytes (NHA) , 2006, Brain Research.

[8]  Anil Kumar,et al.  Virus replication and disease progression inversely correlate with SIV tat evolution in morphine-dependent and SIV/SHIV-infected Indian rhesus macaques. , 2006, Virology.

[9]  S Tsiodras,et al.  Central nervous system manifestations of Mycoplasma pneumoniae infections. , 2005, The Journal of infection.

[10]  I. Grant,et al.  The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease , 2005, AIDS.

[11]  Marlys Witte,et al.  Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells , 2005, Journal of NeuroVirology.

[12]  J. Reynolds,et al.  Cocaine Modulates Dendritic Cell-Specific C Type Intercellular Adhesion Molecule-3-Grabbing Nonintegrin Expression by Dendritic Cells in HIV-1 Patients1 , 2005, The Journal of Immunology.

[13]  S. M. Robinson,et al.  Permeability of the blood–brain barrier to HIV-1 Tat , 2005, Experimental Neurology.

[14]  Shuxian Hu,et al.  Morphine potentiates HIV-1 gp120-induced neuronal apoptosis. , 2005, The Journal of infectious diseases.

[15]  A. Zimmerman,et al.  Neuroglial activation and neuroinflammation in the brain of patients with autism , 2005, Annals of neurology.

[16]  F. Schmitt,et al.  Neuroimaging correlates of HIV-associated BBB compromise , 2004, Journal of Neuroimmunology.

[17]  Cynthia Torres,et al.  Modulation by Morphine of Viral Set Point in Rhesus Macaques Infected with Simian Immunodeficiency Virus and Simian-Human Immunodeficiency Virus , 2004, Journal of Virology.

[18]  M. Avison,et al.  The blood brain barrier in HIV infection. , 2004, Frontiers in bioscience : a journal and virtual library.

[19]  P. Singhal,et al.  Cocaine-induced renal disease , 2004, Expert opinion on drug safety.

[20]  P. Finelli,et al.  Magnetic resonance imaging abnormalities with septic encephalopathy , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[21]  Bernhard Hennig,et al.  HIV‐1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells , 2003, Journal of neuroscience research.

[22]  A. Nath,et al.  Synaptic Transport of Human Immunodeficiency Virus-Tat Protein Causes Neurotoxicity and Gliosis in Rat Brain , 2003, The Journal of Neuroscience.

[23]  P. Peterson,et al.  Opioid G protein-coupled receptors: signals at the crossroads of inflammation. , 2003, Trends in immunology.

[24]  M. Uhl,et al.  Bilateral Striatal Necrosis Associated with Mycoplasma pneumoniae Infection , 2003 .

[25]  A. Nath,et al.  Molecular Basis for Interactions of HIV and Drugs of Abuse , 2002, Journal of acquired immune deficiency syndromes.

[26]  M. Roth,et al.  Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes. , 2002, The Journal of infectious diseases.

[27]  S. Frucht Cocaine-induced persistent dyskinesias , 2001, Neurology.

[28]  M. Mattson,et al.  Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine , 2001, BMC Neuroscience.

[29]  J. Zhang,et al.  Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro , 2001, Neuroscience.

[30]  G. Arendt,et al.  HIV dementia: the role of the basal ganglia and dopaminergic systems , 2000, Journal of psychopharmacology.

[31]  G. Koob Neurobiology of Addiction: Toward the Development of New Therapies , 2000, Annals of the New York Academy of Sciences.

[32]  P. Simmonds,et al.  HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. , 1998, Brain : a journal of neurology.

[33]  E. Allen,et al.  Cerebral infarction in patients with AIDS. , 1997, AJNR. American journal of neuroradiology.

[34]  A. Levey,et al.  Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users , 1996, Annals of neurology.

[35]  C. Petito,et al.  Blood‐brain barrier abnormalities in acquired immunodeficiency syndrome: Immunohistochemical localization of serum proteins in postmortem brain , 1992, Annals of neurology.

[36]  D. Vlahov,et al.  HIV‐1 infection and nervous system abnormalities among a cohort of intravenous drug users , 1991, Neurology.

[37]  D. Dickson,et al.  Cellular localization of an HIV-1 antigen in subacute AIDS encephalitis using an improved double-labeling immunohistochemical method. , 1990, The American journal of pathology.

[38]  S. Buch,et al.  Cocaine-mediated enhancement of virus replication in macrophages: Implications for human immunodeficiency virus-associated dementia , 2011, Journal of NeuroVirology.

[39]  Frederick A. Schmitt,et al.  Acceleration of HIV dementia with methamphetamine and cocaine , 2011, Journal of NeuroVirology.

[40]  Xu Wang,et al.  Methadone enhances human immunodeficiency virus infection of human immune cells. , 2002, The Journal of infectious diseases.

[41]  R. Grant,et al.  Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users , 2002, Journal of General Internal Medicine.

[42]  P. Klotman,et al.  Chapter 47 – HIV-associated Nephropathy , 2009 .

[43]  C. Meltzer,et al.  AIDS-related MR hyperintensity of the basal ganglia. , 1998, AJNR. American journal of neuroradiology.